Navigation Links
NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
Date:5/16/2012

stained 24-hour bronchodilation over 52 weeks.

At Day 1, Week 26 and Week 52 of the GLOW2 study, NVA237 significantly improved lung function (measured by mean trough FEV1) compared to placebo (all p<0.001) and results were similar to those seen with OL tiotropium. At Day 1 and Week 12, 26 and 52, the FEV1 area under the curve (AUC) for 0-4 hr, 0-12 hr, 12-24 hr and 0-24 hr for NVA237 was superior to placebo (p<0.05) and numerically greater than OL tiotropium.

Shinichi Tamura, CEO of Sosei:

"GLOW2 data further illustrate the potential benefits of once daily NVA237 for patients with COPD. NVA237 has been submitted for approval in Europe and Japan and we look forward to a decision from EU regulators that is expected in 2012."

The study also demonstrated that NVA237 improved COPD symptoms, quality of life and reduced exacerbations compared to placebo. NVA237 significantly reduced breathlessness (measured by the transition dyspnea index or TDI, p=0.002), improved health-related quality of life (measured by the St George's Respiratory Questionnaire or SGRQ, p<0.001), reduced use of rescue medication (p=0.039), and increased the percentage of days with no daytime symptoms (p<0.05)compared to placebo over 52 weeks.

For these symptomatic and quality of life indicators, results were numerically similar to those observed with OL tiotropium over the same time period. NVA237 also significantly prolonged the time to first exacerbation and significantly reduced the rate of moderate/severe exacerbations versus placebo over 52 weeks (p=0.001); these effects were similar to OL tiotropium (p=0.001).

Throughout the GLOW2 study, NVA237 was well-tolerated with a similar incidence of adverse events to placebo and OL tiotropium. Serious adverse events were reported less frequently with NVA237 (12.6%) than with either placebo (15.4%) or OL tiotropium (15.0%).


'/>"/>

SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
2. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
3. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
4. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
7. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
9. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
10. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... Israel , August 5, 2015 ... the development of bio-surgical medical devices for tissue ... Series D preferred equity investment. Participants in the ... Sino Biopharmaceutical Ltd., and all existing investors. ... financing will support market introduction and commercialization in ...
(Date:8/5/2015)... 2015   Lipogen , Ltd. launches the ... Lipogen PSPA. Lipogen PSPA is a new, patent-protected ... PSPA is a natural, high-quality ... been successfully demonstrated in two separate, controlled clinical ... socially demanding conditions measured by lower levels of ...
(Date:8/4/2015)... 2015 Karuna Pharmaceuticals, Inc. ("Karuna"), a ... novel product candidate for the treatment of schizophrenia, ... Fund Award from the Wellcome Trust comprising an ... $3.84 million. The funding, along with other capital, ... program KarXT, a potentially innovative therapy for the ...
Breaking Medicine Technology:LifeBond Closes $27 Million Series D Financing Round 2LifeBond Closes $27 Million Series D Financing Round 3What's new in stress management? - Lipogen targets stress management with new PSPA ingredient 2Karuna Receives Wellcome Trust Award to Advance Innovative Clinical Stage Product Candidate for the Treatment of Schizophrenia 2Karuna Receives Wellcome Trust Award to Advance Innovative Clinical Stage Product Candidate for the Treatment of Schizophrenia 3Karuna Receives Wellcome Trust Award to Advance Innovative Clinical Stage Product Candidate for the Treatment of Schizophrenia 4
(Date:8/5/2015)... ... August 05, 2015 , ... While heading back ... requires school physicals and vaccinations to protect children from many preventable diseases. MD ... convenient, hassle free, and affordable for parents to prepare their children for a ...
(Date:8/5/2015)... ... August 05, 2015 , ... Hotze Health & Wellness ... to announce that it has added Electronic Beam Computed Tomography (EBCT) imaging to ... will be used primarily for conducting coronary artery scans and virtual colonoscopies. , ...
(Date:8/5/2015)... (PRWEB) , ... August 05, 2015 , ... ... Stand Foundation to help fight childhood cancer. All proceeds go directly to supporting ... , Alex’s Lemonade Stand Foundation began in the front yard of childhood ...
(Date:8/5/2015)... ... ... makers of the nation’s leading line of recovery drinks, has answered consumers’ calls once more, ... is smooth, rich and ready to travel, in three flavors. It tastes awesome because it’s ... milk and sugar to taste great like other traditional ready to drink coffees. , ...
(Date:8/5/2015)... ... August 05, 2015 , ... Florida Hospital Carrollwood ... for medical and emergency response training. The high-tech human patient simulators provide risk-free ... blink, bleed, cry, suffer a heart attack or show signs of a drug ...
Breaking Medicine News(10 mins):Health News:Pack Up Children’s Back-to-School Essentials at MD Now Urgent Care 2Health News:Pack Up Children’s Back-to-School Essentials at MD Now Urgent Care 3Health News:Pack Up Children’s Back-to-School Essentials at MD Now Urgent Care 4Health News:Hotze Health & Wellness Center Adds EBCT Imaging Services to Preventative Screening Program 2Health News:Hotze Health & Wellness Center Adds EBCT Imaging Services to Preventative Screening Program 3Health News:AskDoctorParker.com Supports Alex’s Lemonade Stand Foundation 2Health News:Kill Cliff® Releases Epic New Product Line – Coffeehouse Quality Cold Brew Coffee in a Can 2Health News:Florida Hospital Carrollwood is Partnering with CAE Healthcare to Help Save Lives with an Emergency Response Training Simulation Lab 2Health News:Florida Hospital Carrollwood is Partnering with CAE Healthcare to Help Save Lives with an Emergency Response Training Simulation Lab 3
... from terminal cancer. The zoo officials are seeking to make ... as possible. // A large node or lymphoma has been ... developing rapidly. ,Even though surgeries have been ... to live for more than a few weeks as the ...
... more than 80 people in Asia and many countries fear that ... various researches are been done to develop a new dug to ... institute have found that Sambucol (an extract from elderberries) is very ... ,This is found to be 99% effective but they also ...
... samples and their personal information about their lifestyle, diet, ... two biggest medical research projects, the British Project called ... still in its infancy and the Biobank would be ... blood samples and your personal lifestyle information and they ...
... new study appearing in the January 18 issue of The ... triggered off when adult neurons try to undergo division. This ... behind the development of the disease. ,"If ... stop neurons from dying prematurely. This could be a fresh ...
... the Indian State of Bihar has been given the task ... Chief Minister is reported to have given him //the task ... ,Sources close to Nitish Kumar said his prime concern ... state, but eliminating mosquitoes was also a priority. The problem ...
... demand for medical staff, it has been proposed to ... role, currently played by nurses, podiatrist surgeons and other ... them into vacant postitions. // ,It has led ... The proposal would be taken up for consideration during ...
Cached Medicine News:Health News:Dividing Nerve Cells Could Trigger Alzheimer's Disease 2Health News:Additional Responsiblities To Be Taken Up By Allied Healthcare Professionals 2
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: